LIVTENCITY™ (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus (CMV) infection
Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO® (lanadelumab)
THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA
Opinion Editorial: Building a Successful Rare Disease Strategy is Our Shared Responsibility
Takeda Releases Report on the Importance of Defining Rare Disease in Canada
